Mixed Bag of Alzheimer's News & Updates
August 3, 2026
Welcome to Greg Rowland’s Alzheimer’s Research Report.
Each report now begins with a brief summary, allowing you to instantly assess its relevance, grasp the core insights, and decide if the full piece warrants a deeper dive.
Due to the significant amount of research and writing to bring each report to life, this is a subscription-only publication. We offer three ways to stay informed:
Monthly Subscription: $10 per month
Annual Subscription: $100 per year (Save $20 annually)
Founder’s Circle: $250 per year (Includes an exclusive monthly video conference to discuss emerging Alzheimer’s treatments in close detail)
I believe the value of a full month of my research reports matches (or exceeds!) the value of a single coffee and muffin. Please consider subscribing so this publication is sustainable. Thank you!
SUMMARY
My report today covers recent news from Biogen, AstraZeneca, and Bristol Myers Squibb. I also discuss Alzheimer’s advocacy work Bill Ritter of WABC-TV is leading.
Finally, I write about the importance of brain health at an early age.
